Trevi Therapeutics (TRVI) Liabilities and Shareholders Equity (2018 - 2026)

Trevi Therapeutics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $179.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 67.85% year-over-year to $179.6 million; the trailing twelve-month figure through Mar 2026 stood at $780.7 million (up 116.5% YoY), and the FY2025 full-year result was $193.4 million, up 74.43% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $179.6 million, down from $193.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $208.3 million in Q2 2025, with the low at $30.4 million in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $116.8 million, with a median of $107.0 million recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity soared 306.26% in 2022 and tumbled 32.4% in 2024.
• Tracing TRVI's Liabilities and Shareholders Equity over 5 years: stood at $123.0 million in 2022, then fell by 27.32% to $89.4 million in 2023, then gained by 24.05% to $110.9 million in 2024, then soared by 74.43% to $193.4 million in 2025, then decreased by 7.15% to $179.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $179.6 million (Q1 2026), $193.4 million (Q4 2025), and $199.4 million (Q3 2025), per Business Quant data.

Peer Comparison